Amicus Therapeutics, Inc. - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 57

Amicus Therapeutics, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Amicus Therapeutics, Inc. - Product Pipeline Review - H2 2011” provides data on the Amicus Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Amicus Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Amicus Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Amicus Therapeutics, Inc. - Brief Amicus Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Amicus Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Amicus Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Amicus Therapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Amicus Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Amicus Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Amicus Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Amicus Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Amicus Therapeutics, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Amicus Therapeutics, Inc.; Amicus Therapeutics, Inc. - Key Therapeutics; Amicus Therapeutics, Inc. - Pipeline Overview and Promising Molecules; Amicus Therapeutics, Inc. - News; Amicus Therapeutics, Inc. - Latest Updates; Amicus Therapeutics, Inc. - Pipeline; Amicus Therapeutics, Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
Amicus Therapeutics, Inc. Snapshot
Amicus Therapeutics, Inc. Overview
Key Information
Key Facts
Amicus Therapeutics, Inc. – Research and Development Overview
Key Therapeutic Areas
Amicus Therapeutics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Amicus Therapeutics, Inc. – Pipeline Products Glance
Amicus Therapeutics, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Amicus Therapeutics, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Amicus Therapeutics, Inc. – Drug Profiles
Alzheimer’s Disease Programme
AT 2101
AT2220
AT3375
Plicera
Amicus Therapeutics, Inc. – Pipeline Analysis
Amicus Therapeutics, Inc. – Pipeline Products by Therapeutic Class
Amicus Therapeutics, Inc. - Pipeline Products By Target
Amicus Therapeutics, Inc. – Pipeline Products by Route of Administration
Amicus Therapeutics, Inc. – Pipeline Products by Molecule Type
Amicus Therapeutics, Inc. – Recent Pipeline Updates
Amicus Therapeutics, Inc. - Dormant Projects
Amicus Therapeutics, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
AT2220
Amicus Therapeutics, Inc. – Company Statement
Amicus Therapeutics, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Sep 30, 2009: Amicus Therapeutics Announces Plan To Initiate Phase 1 Study Of AT2220 For Pompe Disease
Mar 08, 2011: Amicus Announces FDA Agreement To Commence Phase II Study of AT2220 Co-administered With Enzyme Replacement Therapy For Pompe Disease
Oct 02, 2009: Amicus Therapeutics Announces Preliminary Results Of Phase 2 Study With Plicera For Gaucher Disease
Oct 02, 2009: Amicus Therapeutics Announces Preliminary Results Of Phase II Study With Plicera For Gaucher Disease
Financial Deals Landscape
Amicus Therapeutics, Inc., Deals Summary
Amicus Therapeutics, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Amicus Therapeutics Secures $60 Million In Series D Financing
Amicus Therapeutics Secures $55 Million In Series C Financing
Amicus Therapeutics Secures $31 Million In Series B Financing
Licensing Agreements
GlaxoSmithKline Enters Into Licensing Agreement With Amicus Therapeutics For Amigal
Shire Enters Into Licensing Agreement With Amicus Therapeutics
Equity Offering
Amicus Therapeutics Completes Registered Direct Offering Of $18.5 Million
Amicus Therapeutics Completes Initial Public Offering Of $75 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Amicus Therapeutics, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Amicus Therapeutics, Inc. – Pipeline by Stage of Development, H2 2011
Amicus Therapeutics, Inc. - Phase II, H2 2011
Amicus Therapeutics, Inc. - Phase I, H2 2011
Amicus Therapeutics, Inc. - Pipeline By Therapeutic Class, H2 2011
Amicus Therapeutics, Inc. - Pipeline By Target, H2 2011
Amicus Therapeutics, Inc. – Pipeline By Route of Administration, H2 2011
Amicus Therapeutics, Inc. – Pipeline By Molecule Type, H2 2011
Amicus Therapeutics, Inc. – Recent Pipeline Updates, H2 2011
Amicus Therapeutics, Inc. - Dormant Developmental Projects, 2010
Amicus Therapeutics, Inc. - Discontinued Pipeline Products, 2010
Amicus Therapeutics, Inc., Subsidiaries
Amicus Therapeutics, Inc., Deals Summary
Amicus Therapeutics Secures $60 Million In Series D Financing
Amicus Therapeutics Secures $55 Million In Series C Financing
Amicus Therapeutics Secures $31 Million In Series B Financing
GlaxoSmithKline Enters Into Licensing Agreement With Amicus Therapeutics For Amigal
Shire Enters Into Licensing Agreement With Amicus Therapeutics
Amicus Therapeutics Completes Registered Direct Offering Of $18.5 Million
Amicus Therapeutics Completes Initial Public Offering Of $75 Million

List of Figures
Amicus Therapeutics, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Amicus Therapeutics, Inc. – Pipeline by Stage of Development, H2 2011
Amicus Therapeutics, Inc. – Pipeline By Therapeutic Class, H2 2011
Amicus Therapeutics, Inc. - Pipeline By Target, H2 2011

Customers who bought this item also bought

• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Scientific Games Corporation - Company Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Analysis of Google Inc
• Ixia - Company Analysis
• SunGard - Profile - US
• eBay - Strong Execution
• Dell Inc.
• CIBER Inc